Diagonal Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
28
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$125M
- Investors
-
17
Diagonal Therapeutics General Information
Description
Operator of a biotech company intended to discover and develop agonist antibodies. The company's platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery, enabling medical practitioners to deliver therapies to patients, including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
Contact Information
Website
www.diagonaltx.comCorporate Office
- 200 Arsenal Yards Boulevard
- Suite 220
- Watertown, MA 02472
- United States
Corporate Office
- 200 Arsenal Yards Boulevard
- Suite 220
- Watertown, MA 02472
- United States
Diagonal Therapeutics Timeline
Diagonal Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 08-Jan-2026 | $125M | Completed | Product Development | ||
| 2. Early Stage VC (Series A) | 03-Apr-2024 | Completed | Product Development | |||
| 1. Seed Round | $18.2M | $18.2M | Completed | Pre-Clinical Trials |
Diagonal Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | ||||||||
| Seed-2 | 5,250,000 | $0.000010 | $1 | $1 | 1x | $1 | 3.09% | |
| Seed-1 | 10,833,330 | $0.000010 | $1.2 | $1.2 | 1x | $1.2 | 6.38% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Diagonal Therapeutics Comparisons
Industry
Financing
Details
Diagonal Therapeutics Competitors (2)
One of Diagonal Therapeutics’s 2 competitors is Vaderis Therapeutics, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vaderis Therapeutics | Venture Capital-Backed | Basel, Switzerland | ||||
| Creative Biolabs | Corporation | Shirley, NY |
Diagonal Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Diagonal Therapeutics Patents
Diagonal Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231860-A1 | Targeted il-18r bispecifics | Pending | 01-May-2025 | ||
| WO-2026102148-A1 | Alk1 / bmprii bispecific antibodies for treatment of ocular diseases | Pending | 07-Nov-2024 | ||
| US-20260234274-A1 | Activin receptor type ii a/b (actriia/b) antibodies | Pending | 09-Oct-2024 | ||
| WO-2026080757-A2 | Activin receptor type ii a/b (actriia/b) antibodies | Pending | 09-Oct-2024 | ||
| WO-2026080757-A3 | Activin receptor type ii a/b (actriia/b) antibodies | Pending | 09-Oct-2024 | C07K16/28 |
Diagonal Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Diagonal Therapeutics Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Balyasny Asset Management | Hedge Fund | Minority | ||
| Deep Track Capital | Venture Capital | Minority | ||
| EcoR1 Capital | Venture Capital | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| Logos Capital | Hedge Fund | Minority |
Diagonal Therapeutics FAQs
-
When was Diagonal Therapeutics founded?
Diagonal Therapeutics was founded in 2022.
-
Where is Diagonal Therapeutics headquartered?
Diagonal Therapeutics is headquartered in Watertown, MA.
-
What is the size of Diagonal Therapeutics?
Diagonal Therapeutics has 28 total employees.
-
What industry is Diagonal Therapeutics in?
Diagonal Therapeutics’s primary industry is Drug Discovery.
-
Is Diagonal Therapeutics a private or public company?
Diagonal Therapeutics is a Private company.
-
What is the current valuation of Diagonal Therapeutics?
The current valuation of Diagonal Therapeutics is .
-
What is Diagonal Therapeutics’s current revenue?
The current revenue for Diagonal Therapeutics is .
-
How much funding has Diagonal Therapeutics raised over time?
Diagonal Therapeutics has raised $271M.
-
Who are Diagonal Therapeutics’s investors?
Balyasny Asset Management, Deep Track Capital, EcoR1 Capital, Janus Henderson Investors, and Logos Capital are 5 of 17 investors who have invested in Diagonal Therapeutics.
-
Who are Diagonal Therapeutics’s competitors?
Vaderis Therapeutics and Creative Biolabs are competitors of Diagonal Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
